Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis.

Sean M Murphy Philip J JengKathryn E McCollisterJared A LeffAli JalaliMatisyahu ShulmanJoshua D LeeEdward V NunesPatricia NovoJohn RotrosenBruce R Schackman

Published in: Addiction (Abingdon, England) (2021)

Adopting an efficient model of extended-release naltrexone initiation could result in extended-release naltrexone and buprenorphine-naloxone being of comparable economic value from the health-care sector perspective over 24-36 weeks for patients seeking treatment for opioid use disorder at an inpatient detoxification facility.

Keyphrases

healthcare
end stage renal disease
mental health
ejection fraction
newly diagnosed
chronic kidney disease
palliative care
alcohol use disorder
prognostic factors
patient reported